U.S. patent application number 12/518355 was filed with the patent office on 2010-05-27 for effective method of treatment of porcine circovirus and lawsonia intracellularis infections.
This patent application is currently assigned to BOEHRINGER INGELHEIM VETMEDICA, INC.. Invention is credited to Knut Elbers, Vicky Fachinger.
Application Number | 20100129397 12/518355 |
Document ID | / |
Family ID | 39512332 |
Filed Date | 2010-05-27 |
United States Patent
Application |
20100129397 |
Kind Code |
A1 |
Fachinger; Vicky ; et
al. |
May 27, 2010 |
EFFECTIVE METHOD OF TREATMENT OF PORCINE CIRCOVIRUS AND LAWSONIA
INTRACELLULARIS INFECTIONS
Abstract
The present invention relates to the use of porcine circovirus
type 2 (PCV2) antigen and Lawsonia intracellularis (L.
intracellularis) antigen for the prevention, reduction in severity
of, lessening of the clinical symptoms associated therewith,
reduced incidence in a herd, and treatment of swine against Porcine
Circovirus Associated Diseases (PCVAD) and L. intracellularis
associated diseases. In particular, the present invention provides
a method for the treatment or prophylaxis of an animal against PCV2
infection and ileitis caused by L. intracellularis, or a method for
reduction of clinical symptoms caused by or associated with a PCV2
and L. intracellularis infection, comprising the step of
administering an effective amount of PCV2 antigen and L.
intracellularis antigen to an animal in need of such treatment.
Inventors: |
Fachinger; Vicky; (Bad
Soden, DE) ; Elbers; Knut; (Gau Algesheim,
DE) |
Correspondence
Address: |
MICHAEL P. MORRIS;BOEHRINGER INGELHEIM USA CORPORATION
900 RIDGEBURY RD, P O BOX 368
RIDGEFIELD
CT
06877-0368
US
|
Assignee: |
BOEHRINGER INGELHEIM VETMEDICA,
INC.
Saint Joseph
MO
|
Family ID: |
39512332 |
Appl. No.: |
12/518355 |
Filed: |
December 11, 2007 |
PCT Filed: |
December 11, 2007 |
PCT NO: |
PCT/US07/25419 |
371 Date: |
November 17, 2009 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
60869512 |
Dec 11, 2006 |
|
|
|
Current U.S.
Class: |
424/204.1 |
Current CPC
Class: |
A61K 39/105 20130101;
C12N 7/00 20130101; A61K 2039/552 20130101; A61K 2039/70 20130101;
A61P 31/04 20180101; C12N 2750/10022 20130101; A61K 39/12 20130101;
C07K 14/005 20130101; A61K 39/02 20130101; A61P 31/20 20180101;
C12N 2750/10034 20130101 |
Class at
Publication: |
424/204.1 |
International
Class: |
A61K 39/12 20060101
A61K039/12; A61P 31/20 20060101 A61P031/20; A61P 31/04 20060101
A61P031/04 |
Claims
1. A method for the treatment or prophylaxis of an animal against
PCV2 infection and ileitis caused by L. intracellularis, or a
method for reduction of clinical symptoms caused by or associated
with a PCV2 and L. intracellularis infection, comprising the step
of administering an effective amount of PCV2 antigen and L.
intracellularis antigen to an animal in need of such treatment.
2. The method according to claim 1, wherein said animal is
swine.
3. The method according to claim 1, wherein said PCV2 antigen is an
inactivated killed PCV2, modified life PCV2, or a subunit of
PVC2.
4. The method according to claim 1, wherein said PCV2 antigen is
PCV2 ORF2.
5. The method according to claim 1, wherein said PCV2 antigen is
selected from the group consisting of Ingelvac.RTM. CircoFLEX.TM.,
CircoVac.RTM. CircoVent or Suvaxyn PCV2 One Dose.RTM..
6. The method according to claim 5, wherein said PCV2 antigen is
Ingelvac.RTM. CircoFLEX.TM..
7. The method according to claim 1, wherein said L. intracellularis
antigen is a modified live L. intracellularis.
8. The method according to claim 1, wherein said L. intracellularis
antigen is Enterisol.RTM. Ileitis or Enterisol.RTM. Ileitis
B3903.
9. The method according to claim 1, wherein said PCV2 antigen is
Ingelvac.RTM. CircoFLEX.TM. and the L. intracellularis antigen is
Enterisol.RTM. Ileitis or Enterisol.RTM. Ileitis B3903.RTM..
10. The method according to claim 1, wherein said L.
intracellularis antigen is administered prior to the administration
of said PCV2 antigen.
11. The method according to claim 1, wherein said L.
intracellularis antigen is administered at day one of age to week
12 of age.
12. The method according to claim 1, wherein said PCV2 antigen is
administered prior to the administration of said L. intracellularis
antigen.
13. The method according to claim 1, wherein said PCV2 antigen is
administered at week 3 to week 12 of age.
14. The method according to claim 1, wherein 2 to 20 days are in
between the administration of both antigens.
15. The method according to claim 1, further comprising the step of
administering an immune stimulant.
16. The method of claim 1, wherein prior to the administration of
one or both antigens, the incidence of L. intracellularis and/or
PCV2 is determined within a herd or farm.
17. A kit of parts, comprising a container which comprises a PCV2
antigen, preferably Ingelvac.RTM. CircoFLEX.TM., a container which
comprises L. intracellularis antigen, preferably Enterisol.RTM.
Ileitis or Enterisol.RTM. Ileitis B3903, and an instruction manual,
including the information for the administration of said PCV2 and
L. intracellularis antigen.
18. The kit of parts according to claim 17, wherein said container
which comprises the PCV2 antigen and said container which comprises
the L. intracellularis antigen are different containers.
19. The kit of parts according to claim 17, wherein said
instruction manual includes the information that the L.
intracellularis antigen is administered prior to the administration
of the PCV2 antigen.
20. The kit of parts according to claim 17, wherein said
instruction manual includes the information that the L.
intracellularis antigen is administered at day one of age to week
12 of age.
21. The kit of parts according to claim 17, wherein said
instruction manual includes the information that the PCV2 antigen
is administered prior to the administration of the L.
intracellularis antigen.
22. The kit of parts according to claim 17, wherein said
instruction manual includes the information that 2 to 20 days are
in between the administration of both antigens.
23. The kit of parts according to claim 17, wherein said
instruction letter includes the information that the PCV antigen is
administered at week 3 of age to week 12 of age.
24. The kit of parts according to claim 17, further comprising an
immune stimulant and wherein said instruction manual includes the
information that an immune stimulant is also administered.
25. The kit of parts according to claim 17, wherein said
instruction manual includes the information that the incidence of
the L. intracellularis and/or PCV2 is determined within the farm or
specific herd prior to administration of the antigens.
Description
RELATED APPLICATIONS
[0001] This application claims the priority benefit of U.S.
Provisional Application Ser. No. 60/869,512. The teachings and
content of that application are hereby incorporated by reference
herein.
SEQUENCE LISTING
[0002] A sequence listing in electronic format is being provided
herewith. Applicants note that the sequence listing provided
herewith is identical to the sequence listing of WO06/072065, which
is entirely incorporated herein by reference.
BACKGROUND OF THE INVENTION
[0003] 1. Field of the Invention
[0004] The present invention relates to the use of porcine
circovirus type 2 (PCV2) antigen and Lawsonia intracellularis (L.
intracellularis) antigen for the prevention, reduction of clinical
symptoms associated with, and treatment of swine against Porcine
Circovirus Associated Diseases (PCVAD) and L. intracellularis
associated diseases.
[0005] 2. Background of the Invention
[0006] Porcine circovirus type 2 (PCV2) is a small (17-22 nm in
diameter), icoshedral, non-enveloped DNA virus, which contains a
single-stranded circular genome. PCV2 shares approximately 80%
sequence identity with porcine circovirus type 1 (PCV1). However,
in contrast with PCV1, which is generally non-virulent, infection
of swine with PCV2 has recently associated with a number of disease
syndromes which have been collectively named Porcine Circovirus
Associated Diseases (PCVAD) (Allan et al, 2006, IPVS Congress).
Postweaning Multisystemic Wasting Syndrome (PMWS) is generally
regarded to be the major clinical manifestation of PCVAD. (Harding
et al., 1997, Swine Health Prod; 5: 201-203; Kennedy et al., 2000,
J Comp Pathol; 122: 9-24). PMWS affects pigs between 5-18 weeks of
age. PMWS is clinically characterized by wasting, paleness of the
skin, unthriftiness, respiratory distress, diarrhea, icterus, and
jaundice. In some affected swine, a combination of all symptoms
will be apparent while other affected swine will only have one or
two of these symptoms. (Muirhead, 2002, Vet. Rec.; 150: 456) During
necropsy, microscopic and macroscopic lesions also appear on
multiple tissues and organs, with lymphoid organs being the most
common site for lesions. Allan and Ellis, 2000; J Vet. Diagn.
Invest., 12: 3-14). A strong correlation has been observed between
the amount of PCV2 nucleic acid or antigen and the severity of
microscopic lymphoid lesions. Mortality rates for swine infected
with PCV2 can approach 80%. In addition to PMWS, PCV2 has been
associated with several other infections including pseudorabies,
porcine reproductive and respiratory syndrome (PRRS), Glasser's
disease, streptococcal meningitis, salmonellosis, postweaning
colibacillosis, dietetic hepatosis, and suppurative
bronchopneumonia. However, research thus far has not confirmed
whether any of these clinical symptoms are in fact, the direct
result of a PCV2 infection. Moreover, it is not yet known whether
any of these clinical symptoms can be effectively reduced or cured
by an active agent directed against PCV2.
[0007] Approaches to treat PCV2 infections based on a DNA vaccine
are described in U.S. Pat. No. 6,703,023. In WO 03/049703,
production of a live chimeric vaccine is described. This vaccine
comprises a PCV1 backbone in which an immunogenic gene of a
pathogenic PCV2 strains replaces a gene of the PCV1 backbone. WO
99/18214 has provided several PCV2 strains and procedures for the
preparation of a killed PVC2 vaccine. An effective ORF-2 based
subunit vaccine has also been reported in WO 06/072065.
[0008] With growing prevalence of porcine circovirus type 2
associated disease (PCVAD) in nursery and finishing pigs in swine
herds, accurate diagnosis of the disease is critical for effective
health management within the swine industry. That is because some
diseases, such as ileitis caused by Lawsonia intracellularis can
cause clinical symptoms--e.g. diarrhea and weight loss--in nursery
or finishing stage of pigs that can be confused with porcine
circovirus type 2 associated disease (PCVAD).
[0009] Ileitis or Proliferative enteritis (PE) caused by L.
intracellularis is a disease of high economic impact in swine
worldwide. L. intracellularis is an obligate, intracellular
bacterium, described for example in S. McOrist et al., Infection
and Immunity, Vol. 61, No. 19, 4286-4292 (1993) and G. Lawson et
al., J. of Clinical Microbiology, Vol. 31, No. 5, 1136-1142 (1993).
The disease was first identified in swine and characterized by its
gross and microscopic pathology, and later by the demonstration of
the intracellular bacteria within affected cells. The
characterizing pathological feature of the disease is the
proliferation of immature epithelial cells in the crypts of the
ileum (terminal part of the small intestine), the large intestine
or both. Sections of infected tissue are characterized by a
reddened thickening mucosa resembling a "garden hose," and enteric
lesions. The gut thickening ultimately prevents normal gut
function, absorption capabilities, and nutrient transfer. Clinical
effects of the disease are chronic weight loss, unthriftiness,
diarrhea, and death. The disease is of economic importance owing to
death loss, increased medication costs, poor weight gain and
decreased food conversion in affected animals. Clinical cases of
ileitis are observed most notably in pigs 6-20 weeks of age.
However, the presence of L. intracellularis has been confirmed by
polymerase chain reaction (PCR) in recently weaned pigs (3-4 weeks
of age), suggesting subclinical L. intracellularis exposure occur
in the nursery and perhaps, originates from Lawsonia-positive dams
(Mauch and Bilkei (2004) Vet Rec 155: 532; Marsteller et al.
(2003). Swine Health Prod 11:127-130; Stege et al. (2004) Vet Micro
104: 197-206). Current vaccination strategies for the prevention
treatment of proliferative enteritis are limited to swine. For
example, U.S. Pat. Nos. 5,714,375 and 5,885,823 as well as WO
05/011731, all of which are herein incorporated by reference in
their entireties, provide vaccines for the immunization of swine.
Those vaccines are highly effective and known in the market as
Enterisol.RTM. Ileitis or Enterisol.RTM. Ileitis B3903 (Boehringer
Ingelheim Vetmedica Inc., St Joseph, Mo., USA).
DISCLOSURE OF THE INVENTION
[0010] Even if PCVAD, caused by PCV2, may cause similar clinical
symptoms as ileitis in swine and also reduce productivity of swine
industry, its effects were yet not considered to serve or prolong
ileitis. However, due to the confusion in clinical signs caused by
both pathogens, PCV2 and L. intracellularis, a risk exists in
respect to the vaccination strategy for swine herds and swine
farms. Yet, no kind of co-vaccination strategy exists for the
prevention or treatment of pigs against PCVAD and ileitis caused by
L. intracellularis, in particular due to the absence of the
specific awareness of that problem.
[0011] The present invention has identified that problem, and
overcomes it by providing a distinct advance in the state of the
art. According to a general aspect, the present invention provides
a method for the treatment or prophylaxis of an animal against a
PCV2 infection and ileitis caused by L. intracellularis, or a
method for reduction of clinical symptoms caused by or associated
with a PCV2 and L. intracellularis infection, comprising the step
of administering an effective amount of PCV2 antigen and L.
intracellularis antigen to an animal in need of such treatment.
Preferably, said animal is swine. The treatment of swine with an
appropriate PCV2 antigen and L. intracellularis antigen results in
a better performance of the vaccinated pigs, in particular it
results in a higher resistance against PCVAD and ileitis. Moreover,
the immunogenic potential of the PCV2 antigen, preferably of
Ingelvac.RTM. CircoFLEX.TM. (Boehringer Ingelheim Vetmedica, Inc,
St Joseph, Mo., USA) can be enhanced by the administration of L.
intracellularis antigen, preferably by Enterisol.RTM. Ileitis or
Enterisol.RTM. Ileitis B3903 (Boehringer Ingelheim Vetmedica Inc.,
St Joseph, Mo., USA) and vice versa. PCV2 clinical signs and
disease manifestations are greatly magnified when L.
intracellularis infection is present and vice versa.
[0012] The immunogenic compositions and vaccination strategies as
provided herewith can reduce and lessen these effects greatly, and
more than expected. In other words, an unexpected synergistic
effect can be achieved when animals, preferably pigs, are treated
with PCV2 antigen and L. intracellularis antigen. Preferably the
treatment with PCV2 and L. intracellularis antigen occurs prior to
any PCV2 and/or L. intracellularis infection of swine.
[0013] The term "prevention" or "treatment" as used herein means,
but is not limited to a process which includes the administration
of an L. intracellularis and PCV2 antigen to an animal, wherein
said L. intracellularis antigen, when administered to said animal
elicits or is able to elicit an immune response in said animal
against L. intracellularis and wherein said PCV2 antigen, when
administered to said animal elicits or is able to elicit an immune
response in said animal against PCV2. Altogether, such treatment
results in reduction of the clinical symptoms of PCVAD and/or
ileitis.
[0014] The term reduction of clinical symptoms shall mean, but not
limited to the reduction of any of the clinical symptoms associated
with a L. intracellularis and/or PCV2 infection. For example, it
should refer to any reduction of pathogen load, pathogen shedding,
reduction in transmission of and reduction loss of weight gain and
the extent diarrhea.
PCV2 Antigens
[0015] The term "PCV2 antigen", as used herein, refers to any
immunogenic composition which can be used to prevent or treat a
PCV2 infection-associated disease or condition in a subject. The
term "antigen", as used herein, refers in general to an amino acid
sequence, or nucleic acid, which elicits an immune response in a
subject, when administered to that subject. Thus, an antigen can be
of proteineous or nucleic acid origin. A proteineous antigen, as
used herein, includes the full-length sequence of any immunogenic
protein, as well as analogs or fragments thereof. In contrast, a
nucleic acid antigen, as used herein, refers to a nucleic acid
molecule that codes for a full-length sequence of any immunogenic
protein, as well as analogs or fragments thereof. The term
"immunogenic protein, analog or fragment" refers to a fragment of a
protein which includes one or more epitopes and thus elicits the
immune response in a host.
[0016] An "immune response" means but is not limited to the
development in a subset of a cellular and/or antibody-mediated
immune response to the composition or vaccine of interest. Usually,
an "immune response" includes but is not limited to one or more of
the following effects: the production or activation of antibodies,
B cells, helper T cells, suppressor T cells, and/or cytotoxic T
cells, directed specifically to an antigen or antigens included in
the composition or vaccine of interest. Preferably, the host will
display either a therapeutic or a protective immunological (memory)
response such that resistance to new infection will be enhanced
and/or the clinical severity of the disease reduced. Such
protection will be demonstrated by either a reduction in number or
severity of, or lack of one or more of the symptoms associated with
the infection of the pathogen, in the delay of onset of viremia, in
a reduced viral persistence, in a reduction of the overall viral
load and/or in a reduction of viral excretion.
[0017] Thus a preferred PCV2 antigen, as used herein, can induce,
stimulate or enhance the immune response against PCV2. In this
context, the term PCV2 antigen encompasses subunit immunogenic
compositions, as well as compositions containing whole killed, or
attenuated and/or inactivated PCV2.
[0018] By the term "subunit immunogenic composition", a composition
is meant that contains at least one immunogenic polypeptide or
antigen, but not all antigens, derived from or homologous to an
antigen of interest. Such a composition is substantially free of
intact pathogen, e.g. PCV2. Thus, a "subunit immunogenic
composition" is prepared from at least partially purified or
fractionated (preferably substantially purified) immunogenic
polypeptides from PCV2, or recombinant analogs thereof. A preferred
subunit immunogenic composition comprises the PCV2 ORF-2
protein.
[0019] PCV2 ORF-2 protein is a highly conserved domain within PCV2
isolates and thereby, any PCV2 ORF-2 protein or DNA would be
effective as the source of the PCV ORF-2 antigen. Preferred PCV2
ORF-2 proteins are those described in WO06/072065, in particular
the PCV2 ORF-2 protein that is encoded by SEQ ID NO: 11. A further
preferred PCV ORF-2 polypeptide is provided as SEQ ID NO: 5 in
WO06/072065. However, it is understood by those of skill in the art
that any of these sequences could vary by as much as 6-30% in
sequence homology provided that they still retain the antigenic
characteristics that render it useful in immunogenic compositions.
The antigenic characteristics of the PCV2 ORF-2 antigen can be, for
example, estimated by the challenge experiment as provided by
Example 4 of WO06/072065. The antigenic characteristic of a
modified PCV ORF-2 antigen is, for example, still retained, when
the modified antigen confers at least 70%, preferably at least 80%,
even more preferably more preferably 90% of the protective immunity
as compared to the PCV2 ORF-2 protein, encoded by the
polynucleotide sequence of SEQ ID NO: 3 or SEQ ID NO: 4 as provided
in WO06/072065.
[0020] Beside a full-length PCV2 ORF-2 protein, immunogenic
portions of PCV2 ORF-2 protein can also be used as PCV2 antigen.
The term "immunogenic portion", as used herein, refers to truncated
and/or substituted forms, or fragments of PCV2 ORF-2 protein and/or
polynucleotide, respectively. Preferably, such truncated and/or
substituted forms, or fragments will comprise at least 6 contiguous
amino acids from the full-length PCV2 ORF-2 protein. More
preferably, the truncated or substituted forms, or fragments will
have at least 10, more preferably at least 15, and still more
preferably at least 19 contiguous amino acids from the full-length
PCV2 ORF-2 protein. Two preferred sequences in this respect are
provided as SEQ ID NO: 9 and SEQ ID NO: 10 of WO06/072065. It is
further understood that such sequences may be a part of larger
fragments or truncated forms.
[0021] "Sequence Identity" as it is known in the art refers to a
relationship between two or more polypeptide sequences or two or
more polynucleotide sequences, namely a reference sequence and a
given sequence to be compared with the reference sequence. Sequence
identity is determined by comparing the given sequence to the
reference sequence after the sequences have been optimally aligned
to produce the highest degree of sequence similarity, as determined
by the match between strings of such sequences. Upon such
alignment, sequence identity is ascertained on a
position-by-position basis, e.g., the sequences are "identical" at
a particular position if at that position, the nucleotides or amino
acid residues are identical. The total number of such position
identities is then divided by the total number of nucleotides or
residues in the reference sequence to give % sequence identity.
Sequence identity can be readily calculated by known methods,
including but not limited to, those described in Computational
Molecular Biology, Lesk, A. N., ed., Oxford University Press, New
York (1988), Biocomputing: Informatics and Genome Projects, Smith,
D. W., ed., Academic Press, New York (1993); Computer Analysis of
Sequence Data, Part I, Griffin, A. M., and Griffin, H. G., eds.,
Humana Press, New Jersey (1994); Sequence Analysis in Molecular
Biology, von Heinge, G., Academic Press (1987); Sequence Analysis
Primer, Gribskov, M. and Devereux, J., eds., M. Stockton Press, New
York (1991); and Carillo, H., and Lipman, D., SIAM J. Applied
Math., 48: 1073 (1988), the teachings of which are incorporated
herein by reference. Preferred methods to determine the sequence
identity are designed to give the largest match between the
sequences tested. Methods to determine sequence identity are
codified in publicly available computer programs which determine
sequence identity between given sequences. Examples of such
programs include, but are not limited to, the GCG program package
(Devereux, J., et al., Nucleic Acids Research, 12(1):387 (1984)),
BLASTP, BLASTN and FASTA (Altschul, S. F. et al., J. Molec. Biol.,
215:403-410 (1990). The BLASTX program is publicly available from
NCBI and other sources (BLAST Manual, Altschul, S. et al., NCVI NLM
NIH Bethesda, Md. 20894, Altschul, S. F. et al., J. Molec. Biol.,
215:403-410 (1990), the teachings of which are incorporated herein
by reference). These programs optimally align sequences using
default gap weights in order to produce the highest level of
sequence identity between the given and reference sequences. As an
illustration, by a polynucleotide having a nucleotide sequence
having at least, for example, 85%, preferably 90%, even more
preferably 95% "sequence identity" to a reference nucleotide
sequence, it is intended that the nucleotide sequence of the given
polynucleotide is identical to the reference sequence except that
the given polynucleotide sequence may include up to 15, preferably
up to 10, even more preferably up to 5 point mutations per each 100
nucleotides of the reference nucleotide sequence. In other words,
in a polynucleotide having a nucleotide sequence having at least
85%, preferably 90%, even more preferably 95% identity relative to
the reference nucleotide sequence, up to 15%, preferably 10%, even
more preferably 5% of the nucleotides in the reference sequence may
be deleted or substituted with another nucleotide, or a number of
nucleotides up to 15%, preferably 10%, even more preferably 5% of
the total nucleotides in the reference sequence may be inserted
into the reference sequence. These mutations of the reference
sequence may occur at the 5' or 3' terminal positions of the
reference nucleotide sequence or anywhere between those terminal
positions, interspersed either individually among nucleotides in
the reference sequence or in one or more contiguous groups within
the reference sequence. Analogously, by a polypeptide having a
given amino acid sequence having at least, for example, 85%,
preferably 90%, even more preferably 95% sequence identity to a
reference amino acid sequence, it is intended that the given amino
acid sequence of the polypeptide is identical to the reference
sequence except that the given polypeptide sequence may include up
to 15, preferably up to 10, even more preferably up to 5 amino acid
alterations per each 100 amino acids of the reference amino acid
sequence. In other words, to obtain a given polypeptide sequence
having at least 85%, preferably 90%, even more preferably 95%
sequence identity with a reference amino acid sequence, up to 15%,
preferably up to 10%, even more preferably up to 5% of the amino
acid residues in the reference sequence may be deleted or
substituted with another amino acid, or a number of amino acids up
to 15%, preferably up to 10%, even more preferably up to 5% of the
total number of amino acid residues in the reference sequence may
be inserted into the reference sequence. These alterations of the
reference sequence may occur at the amino or the carboxy terminal
positions of the reference amino acid sequence or anywhere between
those terminal positions, interspersed either individually among
residues in the reference sequence or in the one or more contiguous
groups within the reference sequence. Preferably, residue positions
which are not identical differ by conservative amino acid
substitutions. However, conservative substitutions are not included
as a match when determining sequence identity.
[0022] "Sequence homology", as used herein, refers to a method of
determining the relatedness of two sequences. To determine sequence
homology, two or more sequences are optimally aligned, and gaps are
introduced if necessary. However, in contrast to "sequence
identity", conservative amino acid substitutions are counted as a
match when determining sequence homology. In other words, to obtain
a polypeptide or polynucleotide having 95% sequence homology with a
reference sequence, 85%, preferably 90%, even more preferably 95%
of the amino acid residues or nucleotides in the reference sequence
must match or comprise a conservative substitution with another
amino acid or nucleotide, or a number of amino acids or nucleotides
up to 15%, preferably up to 10%, even more preferably up to 5% of
the total amino acid residues or nucleotides, not including
conservative substitutions, in the reference sequence may be
inserted into the reference sequence. Preferably the homolog
sequence comprises a stretch of at least 50, even more preferably
at least 100, even more preferably at least 250, and even more
preferably at least 500 nucleotides.
[0023] A "conservative substitution" refers to the substitution of
an amino acid residue or nucleotide with another amino acid residue
or nucleotide having similar characteristics or properties
including size, hydrophobicity, etc., such that the overall
functionality does not change significantly.
[0024] "Isolated" means altered "by the hand of man" from its
natural state, i.e., if it occurs in nature, it has been changed or
removed from its original environment, or both. For example, a
polynucleotide or polypeptide naturally present in a living
organism is not "isolated," but the same polynucleotide or
polypeptide separated from the coexisting materials of its natural
state is "isolated", as the term is employed herein.
[0025] Thus, the PCV2 antigen as used herein, can be a PCV2 antigen
that comprises or consists of: [0026] i) a PCV2 ORF-2 protein that
comprises the sequence of SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 9,
SEQ ID NO: 10 or SEQ ID NO: 11 of WO06/07065; [0027] ii) a PCV2
ORF-2 protein that is at least 80% homologous to the polypeptide of
i), [0028] iii) any immunogenic portion of the polypeptides of i)
and/or ii) [0029] iv) the immunogenic portion of iii), comprising
at least 10 contiguous amino acids included in the sequences of SEQ
ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 9, SEQ ID NO: 10 or SEQ ID NO:
11 of WO06/072065, [0030] v) a polypeptide that is encoded by a DNA
comprising the sequence of SEQ ID NO: 3 or SEQ ID NO: 4 of
WO06/072065. [0031] vi) any polypeptide that is encoded by a
polynucleotide that is at least 80% homologous to the
polynucleotide of v), [0032] vii) any immunogenic portion of the
polypeptides encoded by the polynucleotide of v) and/or vi) [0033]
viii) the immunogenic portion of vii), wherein polynucleotide
coding for said immunogenic portion comprises at least 30
contiguous nucleotides included in the sequences of SEQ ID NO: 3,
or SEQ ID NO: 4 of WO06/072065.
[0034] Preferably any of the immunogenic portions of PCV2 ORF-2 as
described above have the immunogenic characteristics of PCV2 ORF-2
protein that is encoded by the sequence of SEQ ID NO: 3 or SEQ ID
NO: 4 of WO 06/07065.
[0035] The PCV2 antigen, preferably any of the PCV2 ORF-2 proteins
described above and as used in the immunogenic composition in
accordance with the present invention can be derived in any fashion
including isolation and purification of PCV2 antigen, standard
protein synthesis, and recombinant methodology. Preferred methods
for obtaining PCV2 ORF-2 proteins are provided in WO06/072065, the
teachings and content of which are hereby incorporated by reference
in their entirety. Briefly, susceptible cells are infected with a
recombinant viral vector containing PCV2 ORF-2 DNA coding
sequences, PCV2 ORF-2 polypeptide is expressed by the recombinant
virus, and the expressed PCV2 ORF-2 polypeptide is recovered from
the supernatant by filtration and inactivated by any conventional
method, preferably using binary ethylenimine, which is then
neutralized to stop the inactivation process.
[0036] The PCV2 antigen, as used herein, can be a part of a PCV2
immunogenic composition that comprises i) any of the PCV2 ORF-2
proteins described above and ii) at least a portion of the viral
vector expressing said PCV2 ORF-2 protein, preferably of a
recombinant baculovirus. Moreover, said PCV2 immunogenic
composition can comprise i) any of the PCV2 ORF-2 proteins
described above, ii) at least a portion of the viral vector
expressing said PCV2 ORF-2 protein, preferably of a recombinant
baculovirus, and iii) a portion of the cell culture
supernatant.
[0037] The PCV2 immunogenic composition, as used herein, also
refers to a composition that comprises i) any of the PCV2 ORF-2
proteins described above, ii) at least a portion of the viral
vector expressing said PCV2 ORF-2 protein, iii) a portion of the
cell culture, iv) and inactivating agent, preferably BEI, to
inactivate the recombinant viral vector, wherein about 90% of the
components i) to iii) have a size smaller than 1 .mu.m. Preferably,
BEI is present in concentrations effective to inactivate the
baculovirus.
[0038] The PCV2 immunogenic composition, as used herein, also
refers to a composition that comprises i) any of the PCV2 ORF-2
proteins described above, ii) at least a portion of the viral
vector expressing said PCV2 ORF-2 protein, iii) a portion of the
cell culture, iv) an inactivating agent, preferably BEI, to
inactivate the recombinant viral vector, and v) a neutralization
agent to stop the inactivation mediated by the inactivating agent,
wherein about 90% of the components i) to iii) have a size smaller
than 1 .mu.m. Preferably, if the inactivating agent is BEI, said
composition comprises sodium thiosulfate in equivalent amounts to
BEI.
[0039] Additionally, the PCV2 immunogenic composition, as used
herein, can include one or more veterinary-acceptable carriers. As
used herein, "a veterinary-acceptable carrier" includes any and all
solvents, dispersion media, coatings, adjuvants, stabilizing
agents, diluents, preservatives, antibacterial and antifungal
agents, isotonic agents, adsorption delaying agents, and the like.
Preferably, the PCV2 immunogenic composition comprises PCV2 ORF-2
protein, an adjuvant, preferably Carbopol, and physiological
saline. Diluents include water, saline, dextrose, ethanol,
glycerol, and the like. Isotonic agents can include sodium
chloride, dextrose, mannitol, sorbitol, and lactose, among others.
Stabilizers include albumin and alkali salts of
ethylendiamintetracetic acid, among others. Adjuvants include
aluminium hydroxide and aluminium phosphate, saponins e.g., Quil A,
QS-21 (Cambridge Biotech Inc., Cambridge Mass.), GPI-0100 (Galenica
Pharmaceuticals, Inc., Birmingham, Ala.), water-in-oil emulsion,
oil-in-water emulsion, water-in-oil-in-water emulsion. The
emulsions can be based in particular on light liquid paraffin oil
(European Pharmacopea type); isoprenoid oil such as squalane or
squalene oil resulting from the oligomerization of alkenes, in
particular of isobutene or decene; esters of acids or of alcohols
containing a linear alkyl group, more particularly plant oils,
ethyl oleate, propylene glycol di-(caprylate/caprate), glyceryl
tri-(caprylate/caprate) or propylene glycol dioleate; esters of
branched fatty acids or alcohols, in particular isostearic acid
esters. The oil is used in combination with emulsifiers to form the
emulsion. The emulsifiers are preferably nonionic surfactants, in
particular esters of sorbitan, of mannide (e.g. anhydromannitol
oleate), of glycol, of polyglycerol, of propylene glycol and of
oleic, isostearic, ricinoleic or hydroxystearic acid, which are
optionally ethoxylated, and polyoxypropylene-polyoxyethylene
copolymer blocks, in particular the Pluronic products, especially
L121. See Hunter et al., The Theory and Practical Application of
Adjuvants (Ed. Stewart-Tull, D. E. S.). John Wiley and Sons, NY, pp
51-94 (1995) and Todd et al., Vaccine 15:564-570 (1997). A further
instance of an adjuvant is a compound chosen from the polymers of
acrylic or methacrylic acid and the copolymers of maleic anhydride
and alkenyl derivative. Advantageous adjuvant compounds are the
polymers of acrylic or methacrylic acid which are cross-linked,
especially with polyalkenyl ethers of sugars or polyalcohols. These
compounds are known by the term carbomer (Phameuropa Vol. 8, No. 2,
June 1996). Persons skilled in the art can also refer to U.S. Pat.
No. 2,909,462 which describes such acrylic polymers cross-linked
with a polyhydroxylated compound having at least 3 hydroxyl groups,
preferably not more than 8, the hydrogen atoms of at least three
hydroxyls being replaced by unsaturated aliphatic radicals having
at least 2 carbon atoms. The preferred radicals are those
containing from 2 to 4 carbon atoms, e.g. vinyls, allyls and other
ethylenically unsaturated groups. The unsaturated radicals may
themselves contain other substituents, such as methyl. The products
sold under the name Carbopol (BF Goodrich, Ohio, USA) are
particularly appropriate. They are cross-linked with an allyl
sucrose or with allyl pentaerythritol. Among them, there may be
mentioned Carbopol 974P, 934P and 971P. Most preferred is the use
of Carbopol, in particular the use of Carbopol 971P, preferably in
amounts of about 500 .mu.g to about 5 mg per dose, even more
preferred in an amount of about 750 .mu.g to about 2.5 mg per dose
and most preferred in an amount of about 1 mg per dose. Further
suitable adjuvants include, but are not limited to, the RIBI
adjuvant system (Ribi Inc.), Block co-polymer (CytRx, Atlanta Ga.),
SAF-M (Chiron, Emeryville Calif.), monophosphoryl lipid A, Avridine
lipid-amine adjuvant, heat-labile enterotoxin from E. coli
(recombinant or otherwise), cholera toxin, IMS 1314, or muramyl
dipeptide among many others.
[0040] The PCV2 immunogenic composition, as used herein, also
refers to an immunogenic composition that comprises i) any of the
PCV2 ORF-2 proteins described above, ii) at least a portion of the
viral vector expressing said PCV2 ORF-2 protein, iii) a portion of
the cell culture, iv) an inactivating agent to inactivate the
recombinant viral vector preferably BEI, and v) an neutralization
agent to stop the inactivation mediated by the inactivating agent,
preferably sodium thiosulfate in equivalent amounts to BEI; and vi)
a suitable adjuvant, preferably Carbopol 971; wherein about 90% of
the components i) to iii) have a size smaller than 1 .mu.m.
According to a further aspect, the PCV2 immunogenic composition, as
used herein, further comprises a pharmaceutical acceptable salt,
preferably a phosphate salt in physiologically acceptable
concentrations. Preferably, the pH of said immunogenic composition
is adjusted to a physiological pH, meaning between about 6.5 and
7.5.
[0041] The PCV2 immunogenic composition, as used herein, also
refers to Ingelvac CircoFLEX.RTM., (Boehringer Ingelheim Vetmedica
Inc, St Joseph, Mo., USA), CircoVac.RTM. (Merial SAS, Lyon,
France), CircoVent (Intervet Inc., Millsboro, Del., USA), or
Suvaxyn PCV2 One Dose.RTM. (Fort Dodge Animal Health, Kansas City,
Kans., USA). The most preferred PCV2 antigen, as used herein, is
Ingelvac CircoFLEX.RTM., (Boehringer Ingelheim Vetmedica Inc, St
Joseph, Mo., USA)
Lawsonia intracellularis Antigens
[0042] The term "L. intracellularis" as used herein means the
intracellular, curved gram-negative bacteria described in detail by
C. Gebhart et al., Int'l. J. of Systemic Bacteriology, Vol. 43, No.
3, 533-538 (1993) and S. McOrist et al., Int'l. J. of Systemic
Bacteriology, Vol. 45, No. 4, 820-825 (1995), each of which is
incorporated herein by reference in their entireties, and includes
but is not limited to the isolates described in WO 96/39629 and WO
05/011731. In particular, the term "L. intracellularis" also means,
but is not limited to the isolates deposited under the Budapest
Treaty with the American Type Culture Collection, 10801 University
Boulevard, Manassas, Va. 20110-2209 and assigned ATCC accession
number PTA 4926 or ATCC accession number 55783. Both isolates are
described in WO 96/39629 and WO 05/011731, respectively. The term
"L. intracellularis" also means, but is not limited to any other L.
intracellularis bacteria strain, or isolate, preferably having the
immunogenic properties of at least one of the L. intracellularis
strains described in WO 96/39629 and WO 05/011731, in particular
having the immunogenic properties of at least one of the isolates
deposited under the Budapest Treaty with the American Type Culture
Collection, 10801 University Boulevard, Manassas, Va. 20110-2209
and assigned ATCC accession numbers PTA 4926 or ATCC accession
number 55783.
[0043] A strain or isolate has the "immunogenic properties" of at
least one of the L. intracellularis strains described in WO
96/39629 and WO 05/011731, in particular, of the isolates deposited
as ATCC accession numbers PTA 4926 or ATCC accession number 55783,
when it is detectable at least with one of the anti-L.
intracellularis specific antibodies, described in WO06/01294, in an
detection assay that is also described in WO06/01294. Preferably
those antibodies are selected from the antibodies having the
reference numbers 301:39, 287:6, 268:29, 110:9, 113:2 and 268:18.
Preferably, the detection assay is a sandwich ELISA as described in
Examples 2 and 3 of WO06/12949, whereas antibody 110:9 is used as a
capture antibody and antibody 268:29 is used as a conjugated
antibody. All antibodies disclosed in WO 06/12949 are produced by
hybridoma cells, which are deposited at the Centre for Applied
Microbiology and Research (CAMR) and European Collection of Cell
Cultures ("ECACC"), Salisbury, Wiltshire SP4 OJG, UK, as patent
deposits according to the Budapest Treaty. The date of deposit was
May 11, 2004. HYBRIDOMA CELL LINE 110:9 is successfully deposited
under ECACC Acc. No. 04092204. HYBRIDOMA CELL LINE 113:2 is
successfully deposited under ECACC Acc. No. 04092201. HYBRIDOMA
CELL LINE 268:18 is successfully deposited under ECACC Acc. No.
04092202. HYBRIDOMA CELL LINE 268:29 is successfully deposited
under ECACC Acc. No. 04092206. HYBRIDOMA CELL LINE 287:6 is
successfully deposited under ECACC Acc. No. 04092203. HYBRIDOMA
CELL LINE 301:39 is successfully deposited under ECACC Acc. No.
04092205.
[0044] The term "L. intracellularis antigen" as used herein means,
but is not limited to any composition of matter, that comprises at
least one antigen that can induce, stimulate or enhance the immune
response against a L. intracellularis-caused infection, when
administered to an animal. Preferably, said L. intracellularis
antigen is a complete L. intracellularis bacterium, in particular
in an inactivated form (a so called killed bacterium), a modified
live or attenuated L. intracellularis bacterium (a so called MLB),
any sub-unit, polypeptide or component of L. intracellularis, or
any chimeric vector each comprises at least an immunogenic amino
acid sequence of L. intracellularis. The terms "immunogenic
protein", "immunogenic polypeptide" or "immunogenic amino acid
sequence" as used herein refer to any amino acid sequence which
elicits an immune response in a host against a pathogen comprising
said immunogenic protein, immunogenic polypeptide or immunogenic
amino acid sequence. In particular, an "immunogenic protein",
"immunogenic polypeptide" or "immunogenic amino acid sequence" of
L. intracellularis means any amino acid sequence that codes for an
antigen which elicits an immunological response against L.
intracellularis in a host to which said "immunogenic protein",
"immunogenic polypeptide" or "immunogenic amino acid sequence" is
administered.
[0045] Suitable L. intracellularis antigens include, but are not
limited to those described in EP 1219711; U.S. Pat. No. 6,605,696;
WO 96/39629; WO97/20050; WO 00/69903; WO 00/69904; WO 00/69905; WO
00/69906; WO 02/38594; WO 02/26250; WO 03/06665; WO 04/033631; WO
05/026200; WO 05/011731; WO 06/116763; and/or WO 06/113782, which
are all incorporated entirely herein by reference.
[0046] Preferably, the L. intracellularis antigen is a modified
live L. intracellularis bacteria. Most preferably, said L.
intracellularis antigen is Enterisol.RTM. Ileitis or Enterisol.RTM.
Ileitis B3903 (Boehringer Ingelheim Vetmedica, Inc.).
Effective Amount of Porcine Circovirus and L. intracellularis
Antigen
[0047] The amount of antigen that is effective to elicit an immune
response or is able to elicit an immune response in an animal
depends on the ingredients of the vaccine and the schedule of
administration.
PCV2 Antigen:
[0048] Typically, when an inactivated virus or a modified live
virus preparation is used in the combination vaccine, an amount of
the vaccine containing about 10.sup.2.0 to about 10.sup.9.0
TCID.sub.50 per dose, preferably about 10.sup.3.0 to about
10.sup.8.0 TCID.sub.50 per dose, more preferably, about 10.sup.4.0
to about 10.sup.8.0 TCID.sub.50 per dose. In particular, when
modified live PCV2 is used in the vaccines, the recommended dose to
be administered to the susceptible animal is preferably about
10.sup.3.0 TCID.sub.50 (tissue culture infective dose 50% end
point)/dose to about 10.sup.6.0 TCID.sub.50/dose and more
preferably about 10.sup.4.0 TCID.sub.50/dose to about 10.sup.5.0
TCID.sub.50/dose. In general, the quantity of antigen will be
between 0.2 and 5000 micrograms, and between 10.sup.2.0 and
10.sup.9.0 TCID.sub.50, preferably between 10.sup.3.0 and
10.sup.6.0 TCID.sub.50, and more preferably between 10.sup.4.0 and
10.sup.5.0 TCID.sub.50, when purified antigen is used.
[0049] Sub-unit viral vaccines are normally administered with an
antigen inclusion level of at least 0.2 .mu.g antigen per dose,
preferably with about 0.2 to about 400 .mu.g/dose, still more
preferably with about 0.3 to about 200 .mu.g/dose, even more
preferably with about 0.35 to about 100 .mu.g/dose, still more
preferably with about 0.4 to about 50 .mu.g/dose, still more
preferably with about 0.45 to about 30 .mu.g/dose, still more
preferably with about 0.6 to about 15 .mu.g/dose, even more
preferably with about 0.75 to about 8 .mu.g/dose, even more
preferably with about 1.0 to about 6 .mu.g/dose, and still more
preferably with about 1.3 to about 3.0 .mu.g/dose.
[0050] If PCV ORF-2 antigen is used, the PCV ORF-2 antigen
inclusion level is at least 0.2 .mu.g/PCV2 ORF-2 protein as
described above per dose of the final antigenic composition
(.mu.g/dose), more preferably from about 0.2 to about 400
.mu.g/dose, still more preferably from about 0.3 to about 200
.mu.g/dose, even more preferably from about 0.35 to about 100
.mu.g/dose, still more preferably from about 0.4 to about 50
.mu.g/dose, still more preferably from about 0.45 to about 30
.mu.g/dose, still more preferably from about 0.6 to about 15
.mu.g/dose, even more preferably from about 0.75 to about 8
.mu.g/dose, even more preferably from about 1.0 to about 6
.mu.g/dose, still more preferably from about 1.3 to about 3.0
.mu.g/dose, even more preferably from about 1.4 to about 2.5
.mu.g/dose, even more preferably from about 1.5 to about 2.0
.mu.g/dose, and most preferably about 1.6 .mu.g/dose.
L. intracellularis:
[0051] Typically, when killed L. intracellularis antigen is used in
the vaccine, the vaccine contains an amount of about 10.sup.5 to
about 10.sup.9 colony forming units (CFU) of the L. intracellularis
bacterium per dose, preferably, about 10.sup.6 to about 10.sup.8
(CFU) of the bacterium per dose.
[0052] In particular, when modified live L. intracellularis
bacteria are used in the vaccines, e.g. the bacteria isolates
designated isolate B3903, ATCC accession No. PTA-4926 and
designated isolate N34NP40wk, ATCC accession No. 55783 (both
described in WO 96/39629 and WO 05/011731), the recommended dose to
be administered to the susceptible animal is preferably about 4.5
log 10 TCID.sub.50 (tissue culture infective dose 50% end
point)/dose to about 9.0 log 10 TCID.sub.50/dose and more
preferably about 4.9 log 10 TCID.sub.50/dose to about 6.9 log 10
TCID.sub.50/dose. In a preferred embodiment, the titer of the
vaccine is about 5.9 log 10 TCID.sub.50/dose as determined by
Tissue Culture Infective Dose 50% endpoint dilution assay
(TCID.sub.50). In general, the quantity of immunogen will be
between 50 and 5000 micrograms, and between 4.5 log 10 and 9.0 log
10 TCID.sub.50, more preferably between 4.9 log 10 and 6.9 log 10
TCID.sub.50, when purified bacteria are used.
[0053] Sub-unit vaccines, for example those described in WO
06/116763 or WO 06/113782, are normally administered with an
antigen inclusion level of at least 2 .mu.g antigen per dose,
preferably with about 2 to about 500 .mu.g/dose, still more
preferably with about 5 to about 400 .mu.g/dose, even more
preferably with about 8 to about 300 .mu.g/dose, still more
preferably with about 10 to about 200 .mu.g/dose, still more
preferably with about 10 to about 150 .mu.g/dose, still more
preferably with about 10 to about 100 .mu.g/dose, still more
preferably with about 10 to about 75 .mu.g/dose, still more
preferably with about 10 to about 50 .mu.g/dose, and still more
preferably with about 10 to about 20 .mu.g/dose. Administration
preferably occurs via parenteral route such as intra muscularly or
subcutaneously for example.
Administration of PCV2 and L. intracellularis Antigen
Method of Treatment
[0054] As already mentioned above, according to a general aspect,
the present invention provides a method for the treatment or
prophylaxis of swine against a PCV2 infection and ileitis caused by
L. intracellularis, or a method for reduction of clinical symptoms
caused by or associated with a PCV2 and L. intracellularis
infection, comprising the step of administering an effective amount
of PCV2 antigen and L. intracellularis antigen to an animal in need
of such treatment. Preferably, the PCV antigen is Ingelvac.RTM.
CircoFLEX.TM., and the L. intracellularis antigen is Enterisol.RTM.
Ileitis or Enterisol.RTM. Ileitis B3903. Vaccination with both,
PCV2 and L. intracellularis antigen should be done prior to
infection of pigs with PCV2 and/or L. intracellularis and can occur
simultaneously or consecutively. For example, the positive clinical
effects seen by the prophylactic use of PCV2 antigen, preferably
Ingelvac.RTM. CircoFLEX.TM. can be enhanced by the administration
of L. intracellularis antigen, preferably by Enterisol.RTM. Ileitis
or Enterisol.RTM. Ileitis B3903. Administration of PCV2 antigen,
preferably Ingelvac.RTM. CircoFLEX.TM. prior to administration of
L. intracellularis antigen, e.g. Enterisol.RTM. Ileitis or
Enterisol.RTM. Ileitis B3903 is preferred. Reduction of clinical
symptoms associated with a PCV2 infection, enhance the effect of
the L. intracellularis antigen when administered to pigs. However,
administration of L. intracellularis antigen, preferably
Enterisol.RTM. Ileitis or Enterisol.RTM. Ileitis B3903 prior to
PCV2 antigen, preferably Ingelvac.RTM. CircoFLEX.TM. is also
advantageous for the overall performance of the pigs and within the
meaning of the present invention.
[0055] It has been found that L intracellularis antigen, in
particular Enterisol.RTM. Ileitis or Enterisol.RTM. Ileitis B3903
can be effectively administered to pigs at day one (1) of age or
later. Preferably, administration is done before week 12 of age.
Thus, this finding allows vaccination of pigs prior to their
exposure to L. intracellularis. As already mentioned, treatment of
pigs with L. intracellularis antigen enhances the positive clinical
effects mediated by the PCV2 antigen. PCV2 antigen, in particular
Ingelvac.RTM. CircoFLEX.TM. is administered to pigs at week three
(3) of age or later. Preferably, PCV2 antigen, in particular,
Ingelvac.RTM. CircoFLEX.TM. is administered not later than week 12
of age, preferably not later than week eight (8) of age, and more
preferably not later than week six (6) of age, because clinical
symptoms of PCVAD often strikes when pigs are 8 to 16 weeks of age.
Thus, according to one aspect, the L. intracellularis antigen,
preferably Enterisol.RTM. Ileitis or Enterisol.RTM. Ileitis B3903,
is administered at day one (1) of age or later, preferably at days
one (1) to 21 of age, whereas the PCV2 antigen, preferably
Ingelvac.RTM. CircoFLEX.TM. is administered at week three (3) of
age to week 12 of age, preferably to week six (6) of age. The
antigens are preferably administered in amounts as described above.
In cases where Ingelvac.RTM. CircoFLEX.TM. and Enterisol.RTM.
Ileitis or Enterisol.RTM. Ileitis B3903 are used, administration of
one (1) dose of each antigen is preferred.
[0056] According to a further aspect, the interval between the
administration of L. intracellularis antigen and PCV2 antigen
should be at least 1 to 20 days. However, administration on the
same day is also possible. According to a further aspect of the
invention the interval between the administration of L.
intracellularis antigen and PCV2 antigen should be about 2 to 20
days. According to a further aspect of the invention the interval
between the administration of L. intracellularis antigen and PCV2
antigen should be about 3 to 20 days. According to a further aspect
of the invention the interval between the administration of L.
intracellularis antigen and PCV2 antigen should be about 4 to 20
days. According to a further aspect of the invention the interval
between the administration of L. intracellularis antigen and PCV2
antigen should be about 5 to 20 days. According to a further aspect
of the invention the interval between the administration of L.
intracellularis antigen and PCV2 antigen should be about 6 to 20
days. According to a further aspect of the invention the interval
between the administration of L. intracellularis antigen and PCV2
antigen should be about 7 to 20 days. According to a further aspect
of the invention the interval between the administration of L.
intracellularis antigen and PCV2 antigen should be about 8 to 20
days. According to a further aspect of the invention the interval
between the administration of L. intracellularis antigen and PCV2
antigen should be about 9 to 20 days. According to a further aspect
of the invention the interval between the administration of L.
intracellularis antigen and PCV2 antigen should be about 10 to 20
days. According to a further aspect of the invention the interval
between the administration of L. intracellularis antigen and PCV2
antigen should be about 11 to 20 days. According to a further
aspect of the invention the interval between the administration of
L. intracellularis antigen and PCV2 antigen should be about 12 to
20 days. According to a further aspect of the invention the
interval between the administration of L. intracellularis antigen
and PCV2 antigen should be about 13 to 20 days. According to a
further aspect of the invention the interval between the
administration of L. intracellularis antigen and PCV2 antigen
should be about 14 to 20 days. According to a further aspect of the
invention the interval between the administration of L.
intracellularis antigen and PCV2 antigen should be about 15 to 20
days. According to a further aspect of the invention the interval
between the administration of L. intracellularis antigen and PCV2
antigen should be about 16 to 20 days. According to a further
aspect of the invention the interval between the administration of
L. intracellularis antigen and PCV2 antigen should be at least 17
to 20 days. According to a further aspect of the invention the
interval between the administration of L. intracellularis antigen
and PCV2 antigen should be about 18 to 20 days. According to a
further aspect of the invention the interval between the
administration of L. intracellularis antigen and PCV2 antigen
should be about 19 to 20 days. According to a further aspect of the
invention the interval between the administration of L.
intracellularis antigen and PCV2 antigen should be about 20
days.
[0057] As already mentioned, combined vaccination of pigs with both
antigens (L. intracellularis and PCV2) reduces the overall porcine
circovirus load and virus persistence in the body, as well as the
immunosuppressive effect of porcine circovirus and therefore
enhances the overall performance of vaccinated pigs. Moreover,
administration of PCV2 antigen, preferably Ingelvac.RTM.
CircoFLEX.TM. surprisingly can enhance the resistance against other
pathogens and also significantly enhance the potency of the L.
intracellularis antigen, in particular with respect to reduction in
loss of weight gain. Thus, according to a further aspect of the
present invention, the administration of PCV2 antigen, preferably
Ingelvac.RTM. CircoFLEX.TM. to pigs occurs at week three (3) to
week 12 of age, preferably at week three (3) to week eight (8) of
age week, more preferably at week three (3) to week (6) of age and
prior to or simultaneous with the administration of the L.
intracellularis antigen, preferably Enterisol.RTM. Ileitis or
Enterisol.RTM. Ileitis B3903. Preferably, vaccination with PCV2
antigen occurs prior to vaccination with L. intracelluaris antigen,
e.g. about 1 to 20 days prior to vaccination with L.
intracellularis antigen. Even more preferably, vaccination with
PCV2 antigen occurs about 2 to 20 days prior to vaccination with L.
intracellularis antigen. Even more preferably, vaccination with
PCV2 antigen occurs about 3 to 20 days prior to vaccination with L.
intracellularis antigen. Even more preferably, vaccination with
PCV2 antigen occurs about 4 to 20 days prior to vaccination with L.
intracellularis antigen. Even more preferably, vaccination with
PCV2 antigen occurs about 5 to 20 days prior to vaccination with L.
intracellularis antigen. Even more preferably, vaccination with
PCV2 antigen occurs about 6 to 20 days prior to vaccination with L.
intracellularis antigen. Even more preferably, vaccination with
PCV2 antigen occurs about 7 to 20 days prior to vaccination with L.
intracellularis antigen. Even more preferably, vaccination with
PCV2 antigen occurs about 8 to 20 days prior to vaccination with L.
intracellularis antigen. Even more preferably, vaccination with
PCV2 antigen occurs about 9 to 20 days prior to vaccination with L.
intracellularis antigen. Even more preferably, vaccination with
PCV2 antigen occurs about 10 to 20 days prior to vaccination with
L. intracellularis antigen. Even more preferably, vaccination with
PCV2 antigen occurs about 11 to 20 days prior to vaccination with
L. intracellularis antigen. Even more preferably, vaccination with
PCV2 antigen occurs about 12 to 20 days prior to vaccination with
L. intracellularis antigen. Even more preferably, vaccination with
PCV2 antigen occurs about 13 to 20 days prior to vaccination with
L. intracellularis antigen. Even more preferably, vaccination with
PCV2 antigen occurs about 14 to 20 days prior to vaccination with
L. intracellularis antigen. Even more preferably, vaccination with
PCV2 antigen occurs about 15 to 20 days prior to vaccination with
L. intracellularis antigen. Even more preferably, vaccination with
PCV2 antigen occurs about 16 to 20 days prior to vaccination with
L. intracellularis antigen. Even more preferably, vaccination with
PCV2 antigen occurs about 17 to 20 days prior to vaccination with
L. intracellularis antigen. Even more preferably, vaccination with
PCV2 antigen occurs about 18 to 20 days prior to vaccination with
L. intracellularis antigen. Even more preferably, vaccination with
PCV2 antigen occurs about 19 to 20 days prior to vaccination with
L. intracellularis antigen. Even more preferably, vaccination with
PCV2 antigen occurs about 20 days prior to vaccination with L.
intracellularis antigen.
[0058] According to a further aspect, at least one further dose of
L. intracellularis and/or PCV2 antigen as described above is
administered to the pigs, wherein said subsequent administration(s)
are given at least 14 days beyond the initial or any former
administration. The PCV2 antigen and/or L. intracellularis antigen
can be administered with an immune stimulant. However, in cases of
Ingelvac.RTM. CircoFLEX.TM. and Enterisol.RTM. Ileitis or
Enterisol.RTM. Ileitis B3903, an immune stimulant can be used, but
its use is not necessary. Preferably, said immune stimulant is
given at least twice. Preferably, at least 3 days, more preferably
at least 5 days, and even more preferably at least 7 days are in
between the first and the second or any further administration of
the immune stimulant. Preferably, the immune stimulant is given at
least 10 days, preferably 15 days, even more preferably 20, and
even more preferably at least 22 days beyond the initial
administration of the PCV2 and/or L. intracellularis antigens as
described above. A preferred immune stimulant is, for example,
keyhole limpet hemocyanin (KLH), preferably emulsified with
incomplete Freund's adjuvant (KLH/ICFA). However, it is herewith
understood, that any other immune stimulant known to a person
skilled in the art can also be used. The term "immune stimulant" as
used herein, means any agent or composition that can trigger the
immune response, preferably without initiating or increasing a
specific immune response, for example the immune response against a
specific pathogen. It is further instructed to administer the
immune stimulant in a suitable dose.
[0059] Preferably on the specific antigen administered, the L.
intracellularis antigen and/or PCV2 antigen may be applied through
intravenous, intravascular, intramuscular, intranasal,
intraarterial, intraperitoneal, oral, subcutaneous, intradermal,
intracutaneous, intralobal, intramedullar, or intrapulmonary
routes. In case of Ingelvac.RTM. CircoFLEX.TM., intramuscular
administrations are preferred. In cases of Enterisol.RTM. Ileitis
or Enterisol.RTM. Ileitis B3903, oral application is preferred.
[0060] Besides a general vaccination of herds with L.
intracellularis antigen and PCV2 antigen in order to reduce
clinical symptoms caused by or associated with PCV2 infection
and/or L. intracellularis, an individual vaccination program can be
developed for each farm or swine herd which is affected by swine
pathogens, preferably by PCV2 and L. intracellularis. As already
mentioned, incidence of L. intracellularis and PCV2 within a swine
herd can affect the efficacy of the treatment with PCV2 antigen and
L. intracellularis treatment. In particular, incidence of PCV2 can
affect efficacy of the treatment with L. intracellularis and vice
versa. It is therefore appropriate to estimate first the incidence
of L. intracellularis and/or PCV2 in a herd of a farm prior to
vaccination with L. intracellularis antigen and/or PCV2 antigen.
Incidence of L. intracellularis for example can be estimated by any
diagnostic assay, which allows the detection L. intracellularis
antigen or specific anti-L. intracellularis antibodies. Specific
embodiments of those assays are described for example in WO
06/0202730 and WO 06/012949. PCV2 incidence can be estimated by an
assay described in WO06/072065. After incidence is estimated, an
individual vaccination program can be developed, which reflects the
PCV2 and L. intracellularis incidence of that farm or herd. Thus,
according to a further aspect the present invention relates to a
method for the treatment or prophylaxis of an animal, preferably
swine against a PCV2 infection and ileitis caused by L.
intracellularis, or a method for reduction of clinical symptoms
caused by or associated with a PCV2 and/or L. intracellularis
infection, comprising the steps of: [0061] i. detecting the
incidence of L. intracellularis and/or PCV2 in a swine herd, [0062]
ii. administering to pigs of L. intracellularis positive herds an
effective amount of L. intracellularis antigen and/or PCV2 antigen;
and/or [0063] iii. administering to pigs of PCV2 positive herds an
effective amount of L. intracellularis antigen and/or PCV2
antigen.
[0064] Preferably, administration of L. intracellularis antigen
and/or PCV2 antigen occurs prior to infection of pigs with L.
intracellularis and/or PCV2, most preferably prior to exposure of
pigs with L. intracellularis, and administration of PCV2 antigen
should be done prior to infection of pigs with PCV2. Suitable
administration regimes are described above.
Kit of Parts
[0065] A further aspect relates to a kit, comprising a container
which comprises any of the PCV2 antigens as described herein,
preferably Ingelvac.RTM. CircoFLEX.TM., a container which comprises
any of the L. intracellularis antigens as described herein,
preferably Enterisol.RTM. Ileitis or Enterisol.RTM. Ileitis B3903,
and an instruction manual, including the information for the
administration of the PCV2 and L. intracellularis antigen.
Preferably, the instruction manual includes the administration
information as described supra for the co-vaccination of pigs with
PCV2 and L. intracellularis antigen. For example said instruction
manual comprises the information, that pigs should be treated with
the PCV2 antigen and/or L. intracellularis antigen prior to
infection of said pigs with PCV2 and/or L. intracellularis.
Moreover, said instruction manual also can comprise the
information, that pigs should be vaccinated with the L.
intracellularis antigen prior to the vaccination with the PCV2
antigen. According to a further aspect, the instruction manual
comprises the information, that the PCV2 antigen should be
administered prior to the administration of L. intracellularis. The
sequence in treatment may be influenced by the incidence of both
pathogens within a herd or farm and the effects of one antigen to
the other. For example, L. intracellularis antigen enhances the
immunological potency of the PCV2 antigen, whereas the reduction of
clinical symptoms caused by or associated with PCV2 can enhance the
effectiveness of the L. intracellularis antigen, in particular in
respect to reduction in loss of weight gain. Thus, in cases where
incidence of PCV is predominant, vaccination against PCV2 should be
performed first and vice versa. Moreover the instruction manual can
also comprise the information, that the pigs can be treated with
the L. intracellularis antigen at day 1 of age or later, but
preferably not later than week 12 of age. Moreover, the instruction
manual can also comprise the information, that the vaccination with
the PCV2 antigen should occur at week three (3) of age or later,
but preferably not later than at week 12 of age, preferably not
later than at week (eight) 8, most preferably not later than at
week six (6) of age. Moreover, the instruction manual also
comprises the information that it is more effective to vaccinate
the pigs consecutively with an interval in between the
administration of the two antigens of about one (1) to 20 days, and
more specifically as described above. In the case of Ingelvac.RTM.
CircoFLEX.TM., the instruction manual also includes the information
that each pig is preferably treated with one (1) dose
intramuscularly. In the case of Enterisol.RTM. Ileitis or
Enterisol.RTM. Ileitis B3903, the instruction manual also comprises
the information, that pigs are preferably treated with one (1) dose
administered orally. Moreover, according to a further aspect, said
instruction manual can comprise the information of a second or
further administration(s) of at least one further dose of a PCV2
and/or L. intracellularis antigen, wherein any subsequent
administration is at least 14 days beyond the initial or any former
administration. Preferably, said instruction manual also includes
the information, to administer an immune stimulant. Preferably,
said immune stimulant shall be given at least twice. Preferably, at
least 3, more preferably at least 5, even more preferably at least
7 days are between the first and the second or any further
administration of the immune stimulant. Preferably, the immune
stimulant is given at least 10 days, preferably 15, even more
preferably 20, even more preferably at least 22 days beyond the
initial administration of the PCV2 and/or L. intracellularis
antigen. A preferred immune stimulant is for example is keyhole
limpet hemocyanin (KLH), still preferably emulsified with
incomplete Freund's adjuvant (KLH/ICFA). However, it is herewith
understood, that any other immune stimulant known to a person
skilled in the art can also be used. "Immune stimulant" as used
herein, means any agent or composition that can trigger the immune
response, preferably without initiating or increasing a specific
immune response, for example the immune response against a specific
pathogen. It is further instructed to administer the immune
stimulant in a suitable dose. Moreover, the kit may also comprise a
container, including at least one dose of the immune stimulant,
preferably one dose of KLH, or KLH/ICFA.
Sequence CWU 1
1
1118DNAArtificial SequenceThis is a modified Kozak's sequence
1ccgccatg 826DNAArtificial SequenceThis is a recombinant Eco R1
sequence. 2gaattc 63713DNAPorcine circovirus 3cagctatgac gtatccaagg
aggcgttacc gcagaagaag acaccgcccc cgcagccatc 60ttggccagat cctccgccgc
cgcccctggc tcgtccaccc ccgccaccgc taccgttgga 120gaaggaaaaa
tggcatcttc aacacccgcc tctcccgcac cttcggatat actgtggaga
180aggaaaaatg gcatcttcaa cacccgcctc tcccgcacct tcggatatac
tgtgacgact 240ttgttccccc gggagggggg accaacaaaa tctctatacc
ctttgaatac tacagaataa 300gaaaggttaa ggttgaattc tggccctgct
cccccatcac ccagggtgat aggggagtgg 360gctccactgc tgttattcta
gatgataact ttgtaacaaa ggccacagcc ctaacctatg 420acccatatgt
aaactactcc tcccgccata caatccccca acccttctcc taccactccc
480gttacttcac acccaaacct gttcttgact ccactattga ttacttccaa
ccaaataaca 540aaaggaatca gctttggctg aggctacaaa cctctagaaa
tgtggaccac gtaggcctcg 600gcactgcgtt cgaaaacagt aaatacgacc
aggactacaa tatccgtgta accatgtatg 660tacaattcag agaatttaat
cttaaagacc ccccacttaa accctaaatg aat 7134713DNAPorcine circovirus
4ccgccatgac gtatccaagg aggcgttacc gcagaagaag acaccgcccc cgcagccatc
60ttggccagat cctccgccgc cgcccctggc tcgtccaccc ccgccaccgc taccgttgga
120gaaggaaaaa tggcatcttc aacacccgcc tctcccgcac cttcggatat
actgtcaagg 180ctaccacagt cacaacgccc tcctgggcgg tggacatgat
gagatttaat attgacgact 240ttgttccccc gggagggggg accaacaaaa
tctctatacc ctttgaatac tacagaataa 300gaaaggttaa ggttgaattc
tggccctgct cccccatcac ccagggtgat aggggagtgg 360gctccactgc
tgttattcta gatgataact ttgtaacaaa ggccacagcc ctaacctatg
420acccatatgt aaactactcc tcccgccata caatccccca acccttctcc
taccactccc 480gttacttcac acccaaacct gttcttgact ccactattga
ttacttccaa ccaaataaca 540aaaggaatca gctttggctg aggctacaaa
cctctagaaa tgtggaccac gtaggcctcg 600gcactgcgtt cgaaaacagt
aaatacgacc aggactacaa tatccgtgta accatgtatg 660tacaattcag
agaatttaat cttaaagacc ccccacttga accctaagaa ttc 7135233PRTPorcine
circovirus 5Met Thr Tyr Pro Arg Arg Arg Tyr Arg Arg Arg Arg His Arg
Pro Arg1 5 10 15Ser His Leu Gly Gln Ile Leu Arg Arg Arg Pro Trp Leu
Val His Pro 20 25 30Arg His Arg Tyr Arg Trp Arg Arg Lys Asn Gly Ile
Phe Asn Thr Arg 35 40 45Leu Ser Arg Thr Phe Gly Tyr Thr Val Lys Ala
Thr Thr Val Thr Thr 50 55 60Pro Ser Trp Ala Val Asp Met Met Arg Phe
Asn Ile Asp Asp Phe Val65 70 75 80Pro Pro Gly Gly Gly Thr Asn Lys
Ile Ser Ile Pro Phe Glu Tyr Tyr 85 90 95Arg Ile Arg Lys Val Lys Val
Glu Phe Trp Pro Cys Ser Pro Ile Thr 100 105 110Gln Gly Asp Arg Gly
Val Gly Ser Thr Ala Val Ile Leu Asp Asp Asn 115 120 125Phe Val Thr
Lys Ala Thr Ala Leu Thr Tyr Asp Pro Tyr Val Asn Tyr 130 135 140Ser
Ser Arg His Thr Ile Pro Gln Pro Phe Ser Tyr His Ser Arg Tyr145 150
155 160Phe Thr Pro Lys Pro Val Leu Asp Ser Thr Ile Asp Tyr Phe Gln
Pro 165 170 175Asn Asn Lys Arg Asn Gln Leu Trp Leu Arg Leu Gln Thr
Ser Arg Asn 180 185 190Val Asp His Val Gly Leu Gly Thr Ala Phe Glu
Asn Ser Lys Tyr Asp 195 200 205Gln Asp Tyr Asn Ile Arg Val Thr Met
Tyr Val Gln Phe Arg Glu Phe 210 215 220Asn Leu Lys Asp Pro Pro Leu
Lys Pro225 2306233PRTPorcine circovirus 6Met Thr Tyr Pro Arg Arg
Arg Tyr Arg Arg Arg Arg His Arg Pro Arg1 5 10 15Ser His Leu Gly Gln
Ile Leu Arg Arg Arg Pro Trp Leu Val His Pro 20 25 30Arg His Arg Tyr
Arg Trp Arg Arg Lys Asn Gly Ile Phe Asn Thr Arg 35 40 45Leu Ser Arg
Thr Phe Gly Tyr Thr Val Lys Ala Thr Thr Val Thr Thr 50 55 60Pro Ser
Trp Ala Val Asp Met Met Arg Phe Asn Ile Asp Asp Phe Val65 70 75
80Pro Pro Gly Gly Gly Thr Asn Lys Ile Ser Ile Pro Phe Glu Tyr Tyr
85 90 95Arg Ile Arg Lys Val Lys Val Glu Phe Trp Pro Cys Ser Pro Ile
Thr 100 105 110Gln Gly Asp Arg Gly Val Gly Ser Thr Ala Val Ile Leu
Asp Asp Asn 115 120 125Phe Val Thr Lys Ala Thr Ala Leu Thr Tyr Asp
Pro Tyr Val Asn Tyr 130 135 140Ser Ser Arg His Thr Ile Pro Gln Pro
Phe Ser Tyr His Ser Arg Tyr145 150 155 160Phe Thr Pro Lys Pro Val
Leu Asp Ser Thr Ile Asp Tyr Phe Gln Pro 165 170 175Asn Asn Lys Arg
Asn Gln Leu Trp Leu Arg Leu Gln Thr Ser Arg Asn 180 185 190Val Asp
His Val Gly Leu Gly Thr Ala Phe Glu Asn Ser Lys Tyr Asp 195 200
205Gln Asp Tyr Asn Ile Arg Val Thr Met Tyr Val Gln Phe Arg Glu Phe
210 215 220Asn Leu Lys Asp Pro Pro Leu Glu Pro225
2307756DNAArtificial SequenceThis sequence is from porcine
circovirus type 2, open reading frame 2, together with a portion
from the pGEM T-easy vector. 7gcggccgcgg gaattcgatc cgccatgacg
tatccaagga ggcgttaccg cagaagaaga 60caccgccccc gcagccatct tggccagatc
ctccgccgcc gcccctggct cgtccacccc 120cgccaccgct accgttggag
aaggaaaaat ggcatcttca acacccgcct ctcccgcacc 180ttcggatata
ctgtcaaggc taccacagtc acaacgccct cctgggcggt ggacatgatg
240agatttaata ttgacgactt tgttcccccg ggagggggga ccaacaaaat
ctctataccc 300tttgaatact acagaataag aaaggttaag gttgaattct
ggccctgctc ccccatcacc 360cagggtgata ggggagtggg ctccactgct
gttattctag atgataactt tgtaacaaag 420gccacagccc taacctatga
cccatatgta aactactcct cccgccatac aatcccccaa 480cccttctcct
accactcccg ttacttcaca cccaaacctg ttcttgactc cactattgat
540tacttccaac caaataacaa aaggaatcag ctttggctga ggctacaaac
ctctagaaat 600gtggaccacg taggcctcgg cactgcgttc gaaaacagta
aatacgacca ggactacaat 660atccgtgtaa ccatgtatgt acaattcaga
gaatttaatc ttaaagaccc cccacttgaa 720ccctaagaat tctatcacta
gtgaattcgc ggccgc 756810387DNAArtificial SequenceThis is the
porcine circovirus type 2, ORF2 construct, which includes
baculovirus and pGEM T-easy coding sequences. 8aagctttact
cgtaaagcga gttgaaggat catatttagt tgcgtttatg agataagatt 60gaaagcacgt
gtaaaatgtt tcccgcgcgt tggcacaact atttacaatg cggccaagtt
120ataaaagatt ctaatctgat atgttttaaa acacctttgc ggcccgagtt
gtttgcgtac 180gtgactagcg aagaagatgt gtggaccgca gaacagatag
taaaacaaaa ccctagtatt 240ggagcaataa tcgatttaac caacacgtct
aaatattatg atggtgtgca ttttttgcgg 300gcgggcctgt tatacaaaaa
aattcaagta cctggccaga ctttgccgcc tgaaagcata 360gttcaagaat
ttattgacac ggtaaaagaa tttacagaaa agtgtcccgg catgttggtg
420ggcgtgcact gcacacacgg tattaatcgc accggttaca tggtgtgcag
atatttaatg 480cacaccctgg gtattgcgcc gcaggaagcc atagatagat
tcgaaaaagc cagaggtcac 540aaaattgaaa gacaaaatta cgttcaagat
ttattaattt aattaatatt atttgcattc 600tttaacaaat actttatcct
attttcaaat tgttgcgctt cttccagcga accaaaacta 660tgcttcgctt
gctccgttta gcttgtagcc gatcagtggc gttgttccaa tcgacggtag
720gattaggccg gatattctcc accacaatgt tggcaacgtt gatgttacgt
ttatgctttt 780ggttttccac gtacgtcttt tggccggtaa tagccgtaaa
cgtagtgccg tcgcgcgtca 840cgcacaacac cggatgtttg cgcttgtccg
cggggtattg aaccgcgcga tccgacaaat 900ccaccacttt ggcaactaaa
tcggtgacct gcgcgtcttt tttctgcatt atttcgtctt 960tcttttgcat
ggtttcctgg aagccggtgt acatgcggtt tagatcagtc atgacgcgcg
1020tgacctgcaa atctttggcc tcgatctgct tgtccttgat ggcaacgatg
cgttcaataa 1080actcttgttt tttaacaagt tcctcggttt tttgcgccac
caccgcttgc agcgcgtttg 1140tgtgctcggt gaatgtcgca atcagcttag
tcaccaactg tttgctctcc tcctcccgtt 1200gtttgatcgc gggatcgtac
ttgccggtgc agagcacttg aggaattact tcttctaaaa 1260gccattcttg
taattctatg gcgtaaggca atttggactt cataatcagc tgaatcacgc
1320cggatttagt aatgagcact gtatgcggct gcaaatacag cgggtcgccc
cttttcacga 1380cgctgttaga ggtagggccc ccattttgga tggtctgctc
aaataacgat ttgtatttat 1440tgtctacatg aacacgtata gctttatcac
aaactgtata ttttaaactg ttagcgacgt 1500ccttggccac gaaccggacc
tgttggtcgc gctctagcac gtaccgcagg ttgaacgtat 1560cttctccaaa
tttaaattct ccaattttaa cgcgagccat tttgatacac gtgtgtcgat
1620tttgcaacaa ctattgtttt ttaacgcaaa ctaaacttat tgtggtaagc
aataattaaa 1680tatgggggaa catgcgccgc tacaacactc gtcgttatga
acgcagacgg cgccggtctc 1740ggcgcaagcg gctaaaacgt gttgcgcgtt
caacgcggca aacatcgcaa aagccaatag 1800tacagttttg atttgcatat
taacggcgat tttttaaatt atcttattta ataaatagtt 1860atgacgccta
caactccccg cccgcgttga ctcgctgcac ctcgagcagt tcgttgacgc
1920cttcctccgt gtggccgaac acgtcgagcg ggtggtcgat gaccagcggc
gtgccgcacg 1980cgacgcacaa gtatctgtac accgaatgat cgtcgggcga
aggcacgtcg gcctccaagt 2040ggcaatattg gcaaattcga aaatatatac
agttgggttg tttgcgcata tctatcgtgg 2100cgttgggcat gtacgtccga
acgttgattt gcatgcaagc cgaaattaaa tcattgcgat 2160tagtgcgatt
aaaacgttgt acatcctcgc ttttaatcat gccgtcgatt aaatcgcgca
2220atcgagtcaa gtgatcaaag tgtggaataa tgttttcttt gtattcccga
gtcaagcgca 2280gcgcgtattt taacaaacta gccatcttgt aagttagttt
catttaatgc aactttatcc 2340aataatatat tatgtatcgc acgtcaagaa
ttaacaatgc gcccgttgtc gcatctcaac 2400acgactatga tagagatcaa
ataaagcgcg aattaaatag cttgcgacgc aacgtgcacg 2460atctgtgcac
gcgttccggc acgagctttg attgtaataa gtttttacga agcgatgaca
2520tgacccccgt agtgacaacg atcacgccca aaagaactgc cgactacaaa
attaccgagt 2580atgtcggtga cgttaaaact attaagccat ccaatcgacc
gttagtcgaa tcaggaccgc 2640tggtgcgaga agccgcgaag tatggcgaat
gcatcgtata acgtgtggag tccgctcatt 2700agagcgtcat gtttagacaa
gaaagctaca tatttaattg atcccgatga ttttattgat 2760aaattgaccc
taactccata cacggtattc tacaatggcg gggttttggt caaaatttcc
2820ggactgcgat tgtacatgct gttaacggct ccgcccacta ttaatgaaat
taaaaattcc 2880aattttaaaa aacgcagcaa gagaaacatt tgtatgaaag
aatgcgtaga aggaaagaaa 2940aatgtcgtcg acatgctgaa caacaagatt
aatatgcctc cgtgtataaa aaaaatattg 3000aacgatttga aagaaaacaa
tgtaccgcgc ggcggtatgt acaggaagag gtttatacta 3060aactgttaca
ttgcaaacgt ggtttcgtgt gccaagtgtg aaaaccgatg tttaatcaag
3120gctctgacgc atttctacaa ccacgactcc aagtgtgtgg gtgaagtcat
gcatctttta 3180atcaaatccc aagatgtgta taaaccacca aactgccaaa
aaatgaaaac tgtcgacaag 3240ctctgtccgt ttgctggcaa ctgcaagggt
ctcaatccta tttgtaatta ttgaataata 3300aaacaattat aaatgctaaa
tttgtttttt attaacgata caaaccaaac gcaacaagaa 3360catttgtagt
attatctata attgaaaacg cgtagttata atcgctgagg taatatttaa
3420aatcattttc aaatgattca cagttaattt gcgacaatat aattttattt
tcacataaac 3480tagacgcctt gtcgtcttct tcttcgtatt ccttctcttt
ttcatttttc tcctcataaa 3540aattaacata gttattatcg tatccatata
tgtatctatc gtatagagta aattttttgt 3600tgtcataaat atatatgtct
tttttaatgg ggtgtatagt accgctgcgc atagtttttc 3660tgtaatttac
aacagtgcta ttttctggta gttcttcgga gtgtgttgct ttaattatta
3720aatttatata atcaatgaat ttgggatcgt cggttttgta caatatgttg
ccggcatagt 3780acgcagcttc ttctagttca attacaccat tttttagcag
caccggatta acataacttt 3840ccaaaatgtt gtacgaaccg ttaaacaaaa
acagttcacc tcccttttct atactattgt 3900ctgcgagcag ttgtttgttg
ttaaaaataa cagccattgt aatgagacgc acaaactaat 3960atcacaaact
ggaaatgtct atcaatatat agttgctgat atcatggaga taattaaaat
4020gataaccatc tcgcaaataa ataagtattt tactgttttc gtaacagttt
tgtaataaaa 4080aaacctataa atattccgga ttattcatac cgtcccacca
tcgggcgcgg atcagatctg 4140cagcggccgc gggaattcga tccgccatga
cgtatccaag gaggcgttac cgcagaagaa 4200gacaccgccc ccgcagccat
cttggccaga tcctccgccg ccgcccctgg ctcgtccacc 4260cccgccaccg
ctaccgttgg agaaggaaaa atggcatctt caacacccgc ctctcccgca
4320ccttcggata tactgtcaag gctaccacag tcacaacgcc ctcctgggcg
gtggacatga 4380tgagatttaa tattgacgac tttgttcccc cgggaggggg
gaccaacaaa atctctatac 4440cctttgaata ctacagaata agaaaggtta
aggttgaatt ctggccctgc tcccccatca 4500cccagggtga taggggagtg
ggctccactg ctgttattct agatgataac tttgtaacaa 4560aggccacagc
cctaacctat gacccatatg taaactactc ctcccgccat acaatccccc
4620aacccttctc ctaccactcc cgttacttca cacccaaacc tgttcttgac
tccactattg 4680attacttcca accaaataac aaaaggaatc agctttggct
gaggctacaa acctctagaa 4740atgtggacca cgtaggcctc ggcactgcgt
tcgaaaacag taaatacgac caggactaca 4800atatccgtgt aaccatgtat
gtacaattca gagaatttaa tcttaaagac cccccacttg 4860aaccctaaga
attctatcac tagtgaattc gcggccgccg gccgctccag aattctagaa
4920ggtacccggg atcctttcct gggacccggc aagaaccaaa aactcactct
cttcaaggaa 4980atccgtaatg ttaaacccga cacgatgaag cttgtcgttg
gatggaaagg aaaagagttc 5040tacagggaaa cttggacccg cttcatggaa
gacagcttcc ccattgttaa cgaccaagaa 5100gtgatggatg ttttccttgt
tgtcaacatg cgtcccacta gacccaaccg ttgttacaaa 5160ttcctggccc
aacacgctct gcgttgcgac cccgactatg tacctcatga cgtgattagg
5220atcgtcgagc cttcatgggt gggcagcaac aacgagtacc gcatcagcct
ggctaagaag 5280ggcggcggct gcccaataat gaaccttcac tctgagtaca
ccaactcgtt cgaacagttc 5340atcgatcgtg tcatctggga gaacttctac
aagcccatcg tttacatcgg taccgactct 5400gctgaagagg aggaaattct
ccttgaagtt tccctggtgt tcaaagtaaa ggagtttgca 5460ccagacgcac
ctctgttcac tggtccggcg tattaaaaca cgatacattg ttattagtac
5520atttattaag cgctagattc tgtgcgttgt tgatttacag acaattgttg
tacgtatttt 5580aataattcat taaatttata atctttaggg tggtatgtta
gagcgaaaat caaatgattt 5640tcagcgtctt tatatctgaa tttaaatatt
aaatcctcaa tagatttgta aaataggttt 5700cgattagttt caaacaaggg
ttgtttttcc gaaccgatgg ctggactatc taatggattt 5760tcgctcaacg
ccacaaaact tgccaaatct tgtagcagca atctagcttt gtcgatattc
5820gtttgtgttt tgttttgtaa taaaggttcg acgtcgttca aaatattatg
cgcttttgta 5880tttctttcat cactgtcgtt agtgtacaat tgactcgacg
taaacacgtt aaataaagct 5940tggacatatt taacatcggg cgtgttagct
ttattaggcc gattatcgtc gtcgtcccaa 6000ccctcgtcgt tagaagttgc
ttccgaagac gattttgcca tagccacacg acgcctatta 6060attgtgtcgg
ctaacacgtc cgcgatcaaa tttgtagttg agctttttgg aattatttct
6120gattgcgggc gtttttgggc gggtttcaat ctaactgtgc ccgattttaa
ttcagacaac 6180acgttagaaa gcgatggtgc aggcggtggt aacatttcag
acggcaaatc tactaatggc 6240ggcggtggtg gagctgatga taaatctacc
atcggtggag gcgcaggcgg ggctggcggc 6300ggaggcggag gcggaggtgg
tggcggtgat gcagacggcg gtttaggctc aaatgtctct 6360ttaggcaaca
cagtcggcac ctcaactatt gtactggttt cgggcgccgt ttttggtttg
6420accggtctga gacgagtgcg atttttttcg tttctaatag cttccaacaa
ttgttgtctg 6480tcgtctaaag gtgcagcggg ttgaggttcc gtcggcattg
gtggagcggg cggcaattca 6540gacatcgatg gtggtggtgg tggtggaggc
gctggaatgt taggcacggg agaaggtggt 6600ggcggcggtg ccgccggtat
aatttgttct ggtttagttt gttcgcgcac gattgtgggc 6660accggcgcag
gcgccgctgg ctgcacaacg gaaggtcgtc tgcttcgagg cagcgcttgg
6720ggtggtggca attcaatatt ataattggaa tacaaatcgt aaaaatctgc
tataagcatt 6780gtaatttcgc tatcgtttac cgtgccgata tttaacaacc
gctcaatgta agcaattgta 6840ttgtaaagag attgtctcaa gctcgccgca
cgccgataac aagccttttc atttttacta 6900cagcattgta gtggcgagac
acttcgctgt cgtcgacgta catgtatgct ttgttgtcaa 6960aaacgtcgtt
ggcaagcttt aaaatattta aaagaacatc tctgttcagc accactgtgt
7020tgtcgtaaat gttgtttttg ataatttgcg cttccgcagt atcgacacgt
tcaaaaaatt 7080gatgcgcatc aattttgttg ttcctattat tgaataaata
agattgtaca gattcatatc 7140tacgattcgt catggccacc acaaatgcta
cgctgcaaac gctggtacaa ttttacgaaa 7200actgcaaaaa cgtcaaaact
cggtataaaa taatcaacgg gcgctttggc aaaatatcta 7260ttttatcgca
caagcccact agcaaattgt atttgcagaa aacaatttcg gcgcacaatt
7320ttaacgctga cgaaataaaa gttcaccagt taatgagcga ccacccaaat
tttataaaaa 7380tctattttaa tcacggttcc atcaacaacc aagtgatcgt
gatggactac attgactgtc 7440ccgatttatt tgaaacacta caaattaaag
gcgagctttc gtaccaactt gttagcaata 7500ttattagaca gctgtgtgaa
gcgctcaacg atttgcacaa gcacaatttc atacacaacg 7560acataaaact
cgaaaatgtc ttatatttcg aagcacttga tcgcgtgtat gtttgcgatt
7620acggattgtg caaacacgaa aactcactta gcgtgcacga cggcacgttg
gagtatttta 7680gtccggaaaa aattcgacac acaactatgc acgtttcgtt
tgactggtac gcggcgtgtt 7740aacatacaag ttgctaacgt aatcatggtc
atagctgttt cctgtgtgaa attgttatcc 7800gctcacaatt ccacacaaca
tacgagccgg aagcataaag tgtaaagcct ggggtgccta 7860atgagtgagc
taactcacat taattgcgtt gcgctcactg cccgctttcc agtcgggaaa
7920cctgtcgtgc cagctgcatt aatgaatcgg ccaacgcgcg gggagaggcg
gtttgcgtat 7980tgggcgctct tccgcttcct cgctcactga ctcgctgcgc
tcggtcgttc ggctgcggcg 8040agcggtatca gctcactcaa aggcggtaat
acggttatcc acagaatcag gggataacgc 8100aggaaagaac atgtgagcaa
aaggccagca aaaggccagg aaccgtaaaa aggccgcgtt 8160gctggcgttt
ttccataggc tccgcccccc tgacgagcat cacaaaaatc gacgctcaag
8220tcagaggtgg cgaaacccga caggactata aagataccag gcgtttcccc
ctggaagctc 8280cctcgtgcgc tctcctgttc cgaccctgcc gcttaccgga
tacctgtccg cctttctccc 8340ttcgggaagc gtggcgcttt ctcatagctc
acgctgtagg tatctcagtt cggtgtaggt 8400cgttcgctcc aagctgggct
gtgtgcacga accccccgtt cagcccgacc gctgcgcctt 8460atccggtaac
tatcgtcttg agtccaaccc ggtaagacac gacttatcgc cactggcagc
8520agccactggt aacaggatta gcagagcgag gtatgtaggc ggtgctacag
agttcttgaa 8580gtggtggcct aactacggct acactagaag gacagtattt
ggtatctgcg ctctgctgaa 8640gccagttacc ttcggaaaaa gagttggtag
ctcttgatcc ggcaaacaaa ccaccgctgg 8700tagcggtggt ttttttgttt
gcaagcagca gattacgcgc agaaaaaaag gatctcaaga 8760agatcctttg
atcttttcta cggggtctga cgctcagtgg aacgaaaact cacgttaagg
8820gattttggtc atgagattat caaaaaggat cttcacctag atccttttaa
attaaaaatg 8880aagttttaaa tcaatctaaa gtatatatga gtaaacttgg
tctgacagtt accaatgctt 8940aatcagtgag gcacctatct cagcgatctg
tctatttcgt tcatccatag ttgcctgact 9000ccccgtcgtg tagataacta
cgatacggga gggcttacca tctggcccca gtgctgcaat 9060gataccgcga
gacccacgct caccggctcc agatttatca gcaataaacc agccagccgg
9120aagggccgag cgcagaagtg gtcctgcaac tttatccgcc tccatccagt
ctattaattg 9180ttgccgggaa gctagagtaa gtagttcgcc agttaatagt
ttgcgcaacg ttgttgccat 9240tgctacaggc atcgtggtgt cacgctcgtc
gtttggtatg gcttcattca gctccggttc 9300ccaacgatca aggcgagtta
catgatcccc catgttgtgc aaaaaagcgg ttagctcctt 9360cggtcctccg
atcgttgtca gaagtaagtt ggccgcagtg ttatcactca tggttatggc
9420agcactgcat aattctctta
ctgtcatgcc atccgtaaga tgcttttctg tgactggtga 9480gtactcaacc
aagtcattct gagaatagtg tatgcggcga ccgagttgct cttgcccggc
9540gtcaatacgg gataataccg cgccacatag cagaacttta aaagtgctca
tcattggaaa 9600acgttcttcg gggcgaaaac tctcaaggat cttaccgctg
ttgagatcca gttcgatgta 9660acccactcgt gcacccaact gatcttcagc
atcttttact ttcaccagcg tttctgggtg 9720agcaaaaaca ggaaggcaaa
atgccgcaaa aaagggaata agggcgacac ggaaatgttg 9780aatactcata
ctcttccttt ttcaatatta ttgaagcatt tatcagggtt attgtctcat
9840gagcggatac atatttgaat gtatttagaa aaataaacaa ataggggttc
cgcgcacatt 9900tccccgaaaa gtgccacctg acgtctaaga aaccattatt
atcatgacat taacctataa 9960aaataggcgt atcacgaggc cctttcgtct
cgcgcgtttc ggtgatgacg gtgaaaacct 10020ctgacacatg cagctcccgg
agacggtcac agcttgtctg taagcggatg ccgggagcag 10080acaagcccgt
cagggcgcgt cagcgggtgt tggcgggtgt cggggctggc ttaactatgc
10140ggcatcagag cagattgtac tgagagtgca ccatatgcgg tgtgaaatac
cgcacagatg 10200cgtaaggaga aaataccgca tcaggcgcca ttcgccattc
aggctgcgca actgttggga 10260agggcgatcg gtgcgggcct cttcgctatt
acgccagctg gcgaaagggg gatgtgctgc 10320aaggcgatta agttgggtaa
cgccagggtt ttcccagtca cgacgttgta aaacgacggc 10380cagtgcc
10387920PRTPorcine circovirus 9Ser Tyr Pro Arg Arg Arg Tyr Arg Arg
Arg Arg His His Pro Pro Ser1 5 10 15His Leu Gly Gln
201019PRTPorcine circovirus 10Pro Arg His His Tyr Arg Pro Arg Arg
Lys Asn Gly Ile Phe Asn Thr1 5 10 15Thr Leu Ser11233PRTArtificial
SequenceThis is an amino acid sequence for porcine circovirus type
2, open reading frame 2. 11Met Thr Tyr Pro Arg Arg Arg Tyr Arg Arg
Arg Arg His Arg Pro Arg1 5 10 15Ser His Leu Gly Gln Ile Leu Arg Arg
Arg Pro Trp Leu Val His Pro 20 25 30Arg His Arg Tyr Arg Trp Arg Arg
Lys Asn Gly Ile Phe Asn Thr Arg 35 40 45Leu Ser Arg Thr Phe Gly Tyr
Thr Val Lys Ala Thr Thr Val Arg Thr 50 55 60Pro Ser Trp Ala Val Asp
Met Met Arg Phe Asn Ile Asp Asp Phe Val65 70 75 80Pro Pro Gly Gly
Gly Thr Asn Lys Ile Ser Ile Pro Phe Glu Tyr Tyr 85 90 95Arg Ile Lys
Lys Val Lys Val Glu Phe Trp Pro Cys Ser Pro Ile Thr 100 105 110Gln
Gly Asp Arg Gly Val Gly Ser Thr Ala Val Ile Leu Asp Asp Asn 115 120
125Phe Val Thr Lys Ala Thr Ala Leu Thr Tyr Asp Pro Tyr Val Asn Tyr
130 135 140Ser Ser Arg His Thr Ile Pro Gln Pro Phe Ser Tyr His Ser
Arg Tyr145 150 155 160Phe Thr Pro Lys Pro Val Leu Asp Ser Thr Ile
Asp Tyr Phe Gln Pro 165 170 175Asn Asn Lys Arg Asn Gln Leu Trp Leu
Arg Leu Gln Thr Ser Arg Asn 180 185 190Val Asp His Val Gly Leu Gly
Thr Ala Phe Glu Asn Ser Ile Tyr Asp 195 200 205Gln Asp Tyr Asn Ile
Arg Val Thr Met Tyr Val Gln Phe Arg Glu Phe 210 215 220Asn Leu Lys
Asp Pro Pro Leu Lys Pro225 230
* * * * *